Sonic Healthcare reports strong financials, strategic acquisitions drive growth

Sonic Healthcare Limited reported revenue of A$9.6 billion and a net profit of A$514 million for the 2025 financial year, reflecting 8% revenue growth, including 5% organic expansion. The board announced a final dividend of 63 cents per ordinary share, 35% franked, bringing the total dividend for the year to A$1.07 per share, a 1% increase from FY2024. This performance was supported by strategic acquisitions, including Laboratory Group Dr. Kramer & Colleagues (LADR) for €423 million in July 2025, and Cairo Diagnostics in the USA in August 2025.

These strategic shifts coincided with changes in the company's equity. A notification indicated that 66,371 performance rights ceased on September 24, 2025, due to forfeiture. Concurrently, 49,661 new performance rights were issued to key management personnel, including dr. Colin Goldschmidt (31,554 securities) and mr. Christopher Wilks (18,107 securities), as part of the Sonic Healthcare Performance Rights Plan.

Following these changes, the total number of quoted ordinary fully paid shares stands at 494,237,953. The unquoted equity securities now include 444,207 options expiring 18-NOV-2025, 31,339,912 options expiring various dates, and 294,049 performance rights expiring various dates, reflecting both the cessation and issuance of performance rights during the period.